In recent years, chimeric antigen receptor T (CAR-T) cells targeting CD37 have been developed, and CD37 CAR-T cells have demonstrated strong efficacy against CD37-expressing AML cells, with no observed cytotoxicity toward HSCs (Caulier et al., 2024). Here, CD37 is linked to acute myeloid leukemia.